Platform Technologies Fuel $211B Surge in Precision Cancer Treatment: GT Biopharma, Erasca, Foghorn, OmniAb, and Recursion Pharmaceuticals Poised to Capture Growth in the $212B U.S. Oncology Market

The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, driven by platform-based precision therapies. The U.S. oncology market is projected to surge to $212 billion by 2034, with platform technologies accounting for 60% of total pharma pipeline value. Companies with validated platforms, such as GT Biopharma, Erasca, Foghorn Therapeutics, OmniAb, and Recursion Pharmaceuticals, are capturing premium valuations in the sector.